Loading
CVRx, Inc. Stock: price and insider trades · United States
1 insider bought €66k of shares over the last 90 days, the latest filed 13 Aug 2026.
CVRx, Inc.: what insiders have been doing
CVRx, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 15 insiders published 23 filings.
The record shows 3 purchases on the open market worth €321k, made by 2 insiders, against 6 sales worth €675k by 2 insiders. On balance, insiders were net sellers of €353k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 senior executives. Johnson & Johnson filed the largest sale, €465k, on 10 November 2025.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 23 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 22 purchases and 7 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 56.7 m USD and net income at -53.3 m USD.
The most recent open-market purchase was published on 13 August 2026, 66 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
84
Thresholds
n/a
Buy Volume
€1M
22 ops. · all time
Sell Volume
€685,509
7 ops. · all time
Who traded when
BuySaleJohnson & Johnson5 sales
Mudit K. Jain3 buys
Brent Binkowski1 buy1 sale
Kirk G. Nielsen2 buys
Kevin Hykes1 buy
Since the insiders bought
- -56.2%Entry US$3.08 · Close 16 Oct 2026 US$1.35
- -16.0%Entry US$7.24 · Close at T+90 US$6.08
- -13.3%Entry US$6.99 · Close at T+365 US$6.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,854 of 24,148 companies
16.3
score / 100
Value1
Quality32
FCF yld-110%
Earn yld-144%
EV/EBITDA·
ROE-133%
Gross mgn85%
Net mgn-94%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.39
Analyst consensus
6 analysts2.29/5
US$3.50Target US$4.58(+230%)US$6.00
Income statement
RevenueUS$56.7M
Gross profitUS$48.3M85% margin
EBITDA-US$46.7M-83% margin
Net income-US$53.3M-84.9% margin
Valuation
PER (forward)-0.7x
P/Book1.9x
Beta0.77
Balance sheet & cash
Market capUS$37M
Total debtUS$50.5M
Free Cash Flow-US$40.8M
Debt / Equity298%
Profitability & ownership
ROE-133.4%
ROA-28.7%
% insiders10.3%
% institutions65.8%
Last declaration on 13 August 2026
Declarations84 total
1,309 shares@ US$2.55020.0046% mcap4.2% of flowCommon StockSEC:0001644355-26-000005:0
26,223 shares@ US$2.91470.10% mcap95.8% of flowCommon StockSEC:0001644355-26-000007:0
Canonical exit: 11 Nov 2026 (T+90)
8,720 shares0Common StockSEC:0001566080-26-000002:0
29,005 shares0Common StockSEC:0001172346-26-000004:0
8,720 shares0Common StockSEC:0001246530-26-000002:0
8,720 shares0Common StockSEC:0001523522-26-000007:0
8,720 shares0Common StockSEC:0001584404-26-000006:0
8,720 shares0Common StockSEC:0001644989-26-000002:0
8,720 shares0Common StockSEC:0001871700-26-000002:0
41,000 shares0Common StockSEC:0002056191-26-000004:0
34,000 shares0Common StockSEC:0001329922-26-000006:0
45,000 shares0Common StockSEC:0001869761-26-000002:0
15,000 shares0Common StockSEC:0001644355-26-000002:0
159,000 shares0Common StockSEC:0001467748-26-000002:0
35,000 shares0Common StockSEC:0002028875-26-000002:0
61,000 shares0Common StockSEC:0001869707-26-000002:0
46,800 shares@ US$6.358881.7% of flowCommon StockSEC:0001584404-26-000004:0
Canonical exit: 21 May 2026 (T+90)
600 shares@ US$4.64170.8% of flowCommon StockSEC:0001584404-26-000002:0
Canonical exit: 19 May 2026 (T+90)
16,000 shares@ US$10.0318.3% of flowCommon StockSEC:0001193125-26-007679:0
6,337 shares@ US$10.037.2% of flowCommon StockSEC:0001193125-25-303876:0
500 shares@ US$10.000.6% of flowCommon StockSEC:0001193125-25-296047:0
1,000 shares@ US$10.001.1% of flowCommon StockSEC:0001193125-25-282669:0
52,332 shares@ US$10.2161.1% of flowCommon StockSEC:0001193125-25-274067:0
16,600 shares0Common StockSEC:0001415889-25-021649:0
10,966 shares@ US$5.45288.2% of flowCommon StockSEC:0000950170-25-074682:0
Canonical exit: 13 Aug 2025 (T+90)
25 of 84 declarations
About CVRx, Inc.
CVRx, Inc. is a U.S.-based medical technology company listed on the NASDAQ (United States) and focused on neuromodulation solutions for patients with cardiovascular disease, particularly heart failure. Founded in 2000, the company has built its business around a single commercial product, Barostim, which makes CVRx a highly specialized niche player but also a company with meaningful product-concentration risk. Its operating headquarters and manufacturing activities are in Minneapolis, Minnesota, where CVRx performs final assembly, testing, and packaging of its devices. ([stockanalysis.com](https://stockanalysis.com/stocks/cvrx/company/?utm_source=openai))
Barostim is described by the company as the first FDA-approved medical technology that uses neuromodulation to improve symptoms in heart-failure patients. The implantable device delivers electrical pulses to baroreceptors in the carotid artery wall, aiming to modulate cardiovascular signaling. CVRx also commercializes the platform in Europe, where it has been present since 2012, and in the U.S. since 2020. The business remains in an expansion phase, with commercial adoption still building rather than fully mature. ([ir.cvrx.com](https://ir.cvrx.com/news-releases/news-release-details/cvrx-reports-fourth-quarter-and-full-year-2025-financial-and))
Read moreShow less
From a competitive standpoint, CVRx operates in a narrow segment of the medical-device market at the intersection of cardiology and neuromodulation. Its strategy depends less on portfolio breadth and more on differentiated clinical value, physician adoption, and broader reimbursement access. The company has been expanding its direct U.S. sales organization, and its commercial footprint continued to improve during 2025. At year-end 2025, CVRx reported 252 active implanting centers in the U.S. and 53 U.S. sales territories, up from 223 centers and 48 territories a year earlier. That growth suggests a gradually deepening go-to-market platform, although the company remains much smaller than mainstream cardiovascular device competitors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1235912/000110465926014708/cvrx-20251231x10k.htm))
Geographically, the company is still heavily U.S.-weighted. In 2025, U.S. revenue was $51.9 million, versus $4.8 million in Europe. Management highlighted continued growth in new territories and new accounts, as well as improving physician and patient awareness of Barostim. In February 2026, CVRx reported full-year 2025 revenue of $56.7 million, up 10% year over year, and announced initiation of the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. The company also noted that Category I CPT codes and associated physician reimbursement levels became effective on January 1, 2026, a potentially important commercial milestone that could improve access and reduce friction in the adoption process. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1235912/000110465926014708/cvrx-20251231x10k.htm))
For investors, CVRx is best viewed as a high-risk, high-upside medtech story: a differentiated cardiovascular therapy with regulatory and reimbursement catalysts, but also a narrow revenue base, a limited commercial history, and continued net losses. The company ended 2025 with $75.7 million in cash and cash equivalents and remains in an investment-heavy phase focused on scaling Barostim. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1235912/000110465926014708/cvrx-20251231x10k.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
